Merck, Pfizer line up a big FDA decision on a blockbuster hopeful, staring down some major league competition
Two Big Pharma collaborators — Merck and Pfizer — have moved their SGLT2 diabetes drug hopeful ertugliflozin into the hands of regulators on both sides of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
